Media Summary: In the wake of a government-sponsored clinical trial that showed promising results for the experimental drug CNBC's Meg Tirrell reports on the FDA approval of CNBC's Meg Tirrell reports the latest data on how

Gilead Ceo On Treating Covid 19 We Re Not Finished With Remdesivir - Detailed Analysis & Overview

In the wake of a government-sponsored clinical trial that showed promising results for the experimental drug CNBC's Meg Tirrell reports on the FDA approval of CNBC's Meg Tirrell reports the latest data on how Stocks moved slightly higher in the pre-market Friday following CNBC's "Halftime Report" team discusses a report that says Daniel O'Day says the drug will soon be deployed to the "most urgent" patients following the drug's emergency use authorization ...

Apr.23 -- Dr. Joseph Weinstein, Steward Health Care System chief medical officer, says it's too early to tell if the

Photo Gallery

Gilead CEO on treating Covid-19: 'We're not finished with remdesivir'
Gilead CEO on promising study results for remdesivir Covid-19 treatment
Remdesivir Company CEO: It’s ‘Not A Cure, But A Very Significant Treatment’ | TODAY
Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment
Gilead CEO: We can manufacture enough remdesivir to provide all of the U.S.
Gilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEO
Remdesivir to arrive at hospitals this week, Gilead CEO says
Gilead CEO: Oral version of Covid drug Remdesivir in early testing
Pres. Donald Trump, FDA, Gilead CEO discuss the emergency authorization for Remdesivir
FDA approves Gilead's Remdesivir as a coronavirus treatment
Gilead Drug Remdesivir Is a Rare Example of Foresight in the Coronavirus Pandemic
FDA approves Gilead's Remdesivir as Covid-19 treatment
Sponsored
Sponsored
View Detailed Profile
Gilead CEO on treating Covid-19: 'We're not finished with remdesivir'

Gilead CEO on treating Covid-19: 'We're not finished with remdesivir'

Daniel O'Day,

Gilead CEO on promising study results for remdesivir Covid-19 treatment

Gilead CEO on promising study results for remdesivir Covid-19 treatment

Gilead

Sponsored
Remdesivir Company CEO: It’s ‘Not A Cure, But A Very Significant Treatment’ | TODAY

Remdesivir Company CEO: It’s ‘Not A Cure, But A Very Significant Treatment’ | TODAY

In the wake of a government-sponsored clinical trial that showed promising results for the experimental drug

Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment

Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment

Gilead

Gilead CEO: We can manufacture enough remdesivir to provide all of the U.S.

Gilead CEO: We can manufacture enough remdesivir to provide all of the U.S.

Gilead

Sponsored
Gilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEO

Gilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEO

Gilead

Remdesivir to arrive at hospitals this week, Gilead CEO says

Remdesivir to arrive at hospitals this week, Gilead CEO says

Gilead

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

Gilead CEO

Pres. Donald Trump, FDA, Gilead CEO discuss the emergency authorization for Remdesivir

Pres. Donald Trump, FDA, Gilead CEO discuss the emergency authorization for Remdesivir

Gilead CEO

FDA approves Gilead's Remdesivir as a coronavirus treatment

FDA approves Gilead's Remdesivir as a coronavirus treatment

CNBC's Meg Tirrell reports on the FDA approval of

Gilead Drug Remdesivir Is a Rare Example of Foresight in the Coronavirus Pandemic

Gilead Drug Remdesivir Is a Rare Example of Foresight in the Coronavirus Pandemic

Emergency approval of the antiviral drug

FDA approves Gilead's Remdesivir as Covid-19 treatment

FDA approves Gilead's Remdesivir as Covid-19 treatment

The FDA has approved

Coronavirus: 68% of patients showed improvement using Gilead's Remdesivir in 'compassionate use'

Coronavirus: 68% of patients showed improvement using Gilead's Remdesivir in 'compassionate use'

CNBC's Meg Tirrell reports the latest data on how

Gilead: Additional remdesivir data shows improved recovery

Gilead: Additional remdesivir data shows improved recovery

Stocks moved slightly higher in the pre-market Friday following

Gilead halted after medication Remdesivir flopped in coronavirus trial

Gilead halted after medication Remdesivir flopped in coronavirus trial

CNBC's "Halftime Report" team discusses a report that says

Gilead sets U.S. price for Covid-19 drug remdesivir at $3,120 for typical treatment

Gilead sets U.S. price for Covid-19 drug remdesivir at $3,120 for typical treatment

CNBC's Meg Tirrell breaks down how

Gilead CEO says coronavirus drug remdesivir could reach patients within days

Gilead CEO says coronavirus drug remdesivir could reach patients within days

Daniel O'Day says the drug will soon be deployed to the "most urgent" patients following the drug's emergency use authorization ...

Gilead reports 'positive data' on Remdesivir coronavirus drug trial

Gilead reports 'positive data' on Remdesivir coronavirus drug trial

Gilead

Fauci: Gilead's Remdesivir Drug Trials Show ‘Good News' Against Covid-19 Fight

Fauci: Gilead's Remdesivir Drug Trials Show ‘Good News' Against Covid-19 Fight

Gilead

Gilead Covid-19 Drug Remdesivir Fails in Chinese Trial

Gilead Covid-19 Drug Remdesivir Fails in Chinese Trial

Apr.23 -- Dr. Joseph Weinstein, Steward Health Care System chief medical officer, says it's too early to tell if the